Product
GSK3036656
4 clinical trials
1 indication
Indication
TuberculosisClinical trial
A Parallel Group, Phase 2A, Randomised, Open Label Treatment Study to Assess the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 Administered as a Two Drug Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin-susceptible Pulmonary TuberculosisStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase IIa Open-label Trial to Investigate the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Participants With Drug-sensitive Pulmonary TuberculosisStatus: Completed, Estimated PCD: 2021-12-03
Clinical trial
A Seamless Phase 2B/C Platform Trial to Evaluate Multiple Regimens and Durations of Treatment in Pulmonary TuberculosisStatus: Recruiting, Estimated PCD: 2027-02-24
Clinical trial
A Phase 1, Open-label, Fixed Sequence, 1-way Drug-drug Interaction Study to Investigate the Pharmacokinetics of GSK3036656 and an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel When the Oral Contraceptive is Administered Alone and in Combination With GSK3036656 in Healthy Female Participants of Nonchildbearing Potential Aged 18-65 Years of AgeStatus: Recruiting, Estimated PCD: 2024-10-30